Abstract: The invention provides methods of isolating CD127lo/? immunosuppressive regulatory T cells which can be greatly enriched for FoxP3, methods of expanding the isolated cells, pharmaceutical compositions of such cells, and methods of their use in the treatment of autoimmune and other immune system mediated disorders.
Type:
Grant
Filed:
May 31, 2007
Date of Patent:
April 21, 2015
Assignee:
The Regents of the University of California
Inventors:
Jeffrey A. Bluestone, Weihong Liu, Amy Putnam
Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.
Type:
Grant
Filed:
May 4, 2012
Date of Patent:
April 21, 2015
Assignee:
Omeros Corporation
Inventors:
Thomas Dudler, Wayne R. Gombotz, James Brian Parent, Clark E. Tedford, Anita Kavlie, Urs Beat Hagemann, Herald Reiersen, Sergej Kiprijanov
Abstract: It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed.
Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Type:
Grant
Filed:
September 26, 2014
Date of Patent:
March 31, 2015
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
Type:
Grant
Filed:
April 10, 2012
Date of Patent:
March 24, 2015
Assignees:
The United States of America, as represented by the Secretary, Department of Health & Human Services, Novartis AG
Inventors:
David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Type:
Grant
Filed:
May 30, 2014
Date of Patent:
March 10, 2015
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
Type:
Grant
Filed:
March 28, 2014
Date of Patent:
February 24, 2015
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan
Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
Type:
Grant
Filed:
March 28, 2014
Date of Patent:
February 24, 2015
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Rebecca S. Hoffman, Elliot Keith Chartash, Lori K. Taylor, George Richard Granneman, Philip Yan
Abstract: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
April 6, 2012
Date of Patent:
February 10, 2015
Assignees:
University of Leicester, Omeros Corporation
Inventors:
Gregory A. Demopulos, Thomas Dudler, Hans-Wilhelm Schwaeble
Abstract: Purified immunocytes were analyzed for expression frequencies, and the NKIR gene expressed specifically in natural killer (NK) cells was successfully identified. The NKIR gene encodes a receptor. Agonists and antagonists for the receptor can be identified by using the receptor.
Abstract: scFv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with CDRs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scFv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scFV that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scFv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody.
Type:
Grant
Filed:
July 10, 2007
Date of Patent:
January 20, 2015
Assignee:
Esbatech, An Alcon Biomedical Research Unit, LLC
Inventors:
Adrian Auf Der Maur, Alcide Barberis, David M. Urech, Peter Lichtlen
Abstract: The present invention provides a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof.
Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
Type:
Grant
Filed:
June 26, 2013
Date of Patent:
December 23, 2014
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Type:
Grant
Filed:
April 18, 2014
Date of Patent:
December 16, 2014
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
Type:
Grant
Filed:
August 2, 2013
Date of Patent:
December 9, 2014
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Min Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
Abstract: The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
Type:
Grant
Filed:
May 21, 2008
Date of Patent:
December 9, 2014
Assignee:
ZymoGenetics, Inc.
Inventors:
Wenfeng Xu, Wayne R. Kindsvogel, Zhi Chen, Steven D. Hughes, Yasmin A. Chandrasekher, Stacey R. Dillon, Joyce M. Lehner, Anthony W. Siadak, Pallavar V. Sivakumar, Margaret D. Moore
Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
Type:
Grant
Filed:
August 1, 2013
Date of Patent:
November 25, 2014
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Min Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
Type:
Grant
Filed:
April 11, 2005
Date of Patent:
November 18, 2014
Assignee:
AbbVie Biotechnology Ltd.
Inventors:
Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
Abstract: The present invention provides a T-cell receptor (TCR) which binds to a peptide from latent membrane protein 2 (LMP-2) from the Epstein Barr Virus (EBV) having the amino acid sequence CLGGLLTMV (SEQ ID No. 1) when presented by a major histocampatability complex (MHC) molecule. The present invention also provides a nucleotide sequence encoding such a TCR, a vector comprising such a nucleotide sequence and its use to produce a EBV-specific T-cell. The present invention also provides the use of EBV-specific T-cell for cellular immunotherapy.